Boccuni, LeonardoAbellaneda-Pérez, KilianMartín-Fernández, JesúsLeno Colorado, DavidRoca-Ventura, AlbaPrats Bisbe, AlbaBuloz Osorio, Edgar AntonioBartrés-Faz, DavidBargalló Alabart, NúriaCabello-Toscano, MaríaPariente, José CarlosMuñoz-Moreno, EmmaTrompetto, CarloMarinelli, LucioVillalba Martínez, GloriaDuffau, HuguesPascual-Leone, ÁlvaroTormos Muñoz, Josep María2024-05-142024-05-142023Boccuni L, Abellaneda-Pérez K, Martín-Fernández J, Leno-Colorado D, Roca-Ventura A, Prats Bisbe A, et al. Neuromodulation-induced prehabilitation to leverage neuroplasticity before brain tumor surgery: a single-cohort feasibility trial protocol. Front Neurol. 2023 Oct 2;14:1243857. DOI: 10.3389/fneur.2023.12438571664-2295http://hdl.handle.net/10230/60124Introduction: Neurosurgery for brain tumors needs to find a complex balance between the effective removal of targeted tissue and the preservation of surrounding brain areas. Neuromodulation-induced cortical prehabilitation (NICP) is a promising strategy that combines temporary inhibition of critical areas (virtual lesion) with intensive behavioral training to foster the activation of alternative brain resources. By progressively reducing the functional relevance of targeted areas, the goal is to facilitate resection with reduced risks of neurological sequelae. However, it is still unclear which modality (invasive vs. non-invasive neuromodulation) and volume of therapy (behavioral training) may be optimal in terms of feasibility and efficacy. Methods and analysis: Patients undertake between 10 and 20 daily sessions consisting of neuromodulation coupled with intensive task training, individualized based on the target site and neurological functions at risk of being compromised. The primary outcome of the proposed pilot, single-cohort trial is to investigate the feasibility and potential effectiveness of a non-invasive NICP protocol on neuroplasticity and post-surgical outcomes. Secondary outcomes investigating longitudinal changes (neuroimaging, neurophysiology, and clinical) are measured pre-NICP, post-NICP, and post-surgery. Ethics and dissemination: Ethics approval was obtained from the Research Ethical Committee of Fundació Unió Catalana d'Hospitals (approval number: CEI 21/65, version 1, 13/07/2021). The results of the study will be submitted to a peer-reviewed journal and presented at scientific congresses. Clinical trial registration: ClinicalTrials.gov, identifier NCT05844605.application/pdfeng© 2023 Boccuni, Abellaneda-Pérez, Martín-Fernández, Leno-Colorado, Roca-Ventura, Prats Bisbe, Buloz-Osorio, Bartrés-Faz, Bargalló, Cabello-Toscano, Pariente, Muñoz-Moreno, Trompetto, Marinelli, Villalba-Martinez, Duffau, Pascual-Leone and Tormos Muñoz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/articlehttp://dx.doi.org/10.3389/fneur.2023.1243857Brain tumorClinical trialNeuro-oncologyNeuromodulationNeuroplasticityNeurorehabilitationNeurosurgeryPrehabilitationinfo:eu-repo/semantics/openAccess